Board of Directors
Cam L. Garner
One of our co-founders and chairman since August 2006, Mr. Garner is a pharmaceutical executive with over 40 years of diverse experience in the healthcare industry ranging from diagnostics and devices to pharmaceuticals. He was part of the senior management team that built Hybritech, Inc. After facilitating the acquisition of Dura Pharmaceuticals, Inc. in 1989 for $5 million, Mr. Garner served as Chief Executive Officer and Chairman until the company was sold in November 2000, for $1.8 billion to Elan Corporation. During his tenure at Dura, annual revenues grew from $2 million to over $300 million. Mr. Garner has founded or co-founded numerous specialty pharmaceutical companies in San Diego including Alastin Skincare, Inc., Cadence Pharmaceuticals, Inc., DJ Pharma, Elevation Pharmaceuticals, Evoke Pharma, Kalyra Pharmaceuticals, Inc., Meritage Pharma, Inc., Neurelis, Inc., OrPro Therapeutics, SkinMedica, Somaxon Pharmaceuticals Inc., Tokalas, Inc., Verus Pharmaceuticals, Inc., Xcel Pharmaceuticals, Inc., Zavante Therapeutics, Inc. and Zogenix, Inc. In addition to Zogenix, Mr. Garner currently serves as Chairman of Evoke, Kalyra, OrPro, and Zavante . Mr. Garner is also Chairman-elect and serves on the Executive Committee of UCSD Moores Cancer Center, San Diego. Mr. Garner earned his B.A. in Biology from Virginia Wesleyan College and an M.B.A. from Baldwin-Wallace College.
Louis C. Bock
A member of our board of directors since August 2006, Mr. Bock has extensive clinical and leadership experience in the biotechnology and biopharmaceutical industries, including experience in research, project management, business development, and sales. Mr. Bock is a private investor and has served on our Board since inception. From September 1997 to July 2014, he was Managing Director of Scale Venture Partners, a venture capital firm. Previously, Mr. Bock held various positions in research, project management, business development and sales at Gilead Sciences, Inc., from September 1989 to September 1997. Prior to Gilead, he was a research associate at Genentech, Inc. from November 1987 to September 1989. He currently serves as a director of Ascenta Therapeutics, Inc., diaDexus, Inc., VaxGen, Inc., Horizon Pharma, Inc., Orexigen Therapeutics, Inc. and Sonexa Therapeutics, Inc. and is responsible for Scale Venture Partners’ prior investments in Seattle Genetics, Prestwick Pharmaceuticals, Inc. and Somaxon Pharmaceuticals, Inc. Mr. Bock received his B.S. in Biology from California State University, Chico and an M.B.A. from California State University, San Francisco.
James B. Breitmeyer, M.D., Ph.D.
Dr. Breitmeyer has served as a member of our board of directors since March 2014. He currently serves as President, CEO and Director of Oncternal Therapeutics, Inc. a clinical-stage oncology biotech developing first-in-class therapies for both rare and common malignancies. He was most recently President of Bavarian Nordic, Inc. in the United States and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark. He previously served as the acting Chief Medical Officer of Zogenix Inc. in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute and held a variety of positions at Serono Laboratories Inc. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer holds a BA in Chemistry from the University of California, Santa Cruz and an M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology.
Stephen Farr, Ph.D.
Stephen J. Farr, Ph.D. is one of our co-founders, a member of our board of directors and has served as our Chief Executive Officer since April 2015, leading our strategy on developing drugs in rare orphan neurological disorders. In his original role as President and Chief Operating Officer since the founding of Zogenix in 2006, Dr. Farr led the development and FDA approval of the Company’s first two drug products. Prior to starting Zogenix, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006. His last position was Aradigm’s Sr. Vice President and Chief Scientific Officer, with responsibility for research and development as well as business development. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of biopharmaceutics. While there, he built an internationally recognized research group working in drug delivery science with a focus on pulmonary drug delivery.
Dr. Farr is a member of the board of directors of SteadyMed (NASDAQ: STDY) and two private companies, Oscillari, LLC and Flow Pharma, Inc. He is author/co-author of over 180 scientific publications and patents and retains his academic interests as adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, USA. Dr. Farr received a BSc (Hons) Pharmacy degree from De Montfort University, UK and holds his Ph.D. degree in Pharmaceutics from the University of Wales.
Caroline M. Loewy
A member of the Zogenix board of directors since September 2020, Ms. Loewy has more than 25 years of experience in the biopharmaceutical industry and currently serves as a strategic business and financial advisor to life science companies. She has held numerous executive roles throughout her career, most recently as co-founder, Chief Financial Officer, and Chief Business Officer of Achieve Life Sciences, Inc. Prior to Achieve Life Sciences, Ms. Loewy served as Chief Financial Officer of Tobira Therapeutics, Corcept Therapeutics and Poniard Pharmaceuticals. Earlier in her career, Ms. Loewy was Executive Director of Biotechnology Equity Research at Morgan Stanley and served as Managing Director of Biotechnology Equity Research at Prudential Securities. She began her career as a financial analyst at BankAmerica Corporation.
Ms. Loewy serves on the Boards of Directors of PhaseBio Pharmaceuticals, Aptose Biosciences and CymaBay Therapeutics. She is a founding board member of the Global Genes Project, a leading rare disease patient advocacy organization, a member of the Steering Committee of the Forum for Collaborative Research in Rare Diseases, and a co-founder of KCNQ2 Cure Alliance, a non-profit advancing research for the rare disease KCNQ2 epileptic encephalopathy. Ms. Loewy holds an M.B.A. and M.S. from Carnegie Mellon University and a B.A. from the University of California, Berkeley.
Erle T. Mast
A member of our board of directors since May 2008, Mr. Mast has previous experience as a chief financial officer of various companies in the healthcare industry and in providing accounting, auditing and consulting services while at Deloitte & Touche, LLP. Mr. Mast was a co-founder of and served as Executive Vice President, Chief Financial Officer of Clovis Oncology, Inc. from May 2009 to March 2016. From July 2002 to May 2008, Mr. Mast served as Executive Vice President and Chief Financial Officer of Pharmion Corporation, until its acquisition by Celgene Corporation. From 2000 to 2002, after Elan Pharma International Ltd. acquired Dura Pharmaceuticals, Inc., Mr. Mast served as Chief Financial Officer for the Global Biopharmaceuticals business unit of Elan. From 1997 to 2000, Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. From 1984 to 1997, Mr. Mast held positions of increasing responsibility at Deloitte & Touche, LLP, serving most recently as Partner, where he provided accounting, auditing and business consulting services to companies in various industries, including the healthcare, pharmaceutical, biotech and manufacturing industries. Mr. Mast received a degree in Business Administration from California State University, Bakersfield.
Mary E. Stutts
A member of the Zogenix board of directors since September 2020, Ms. Stutts currently serves as the Senior Vice President of Corporate Relations for Sumitovant Biopharma, the global parent to five biopharma companies. Prior to Sumitovant, Ms. Stutts served as Chief Inclusion, Diversity & Health Equity Officer at Stanford Health Care. Prior to that role, she served as Vice President, External Affairs, at Comcast NBCUniversal, and has provided global corporate relations leadership through her roles in the biotechnology, pharmaceutical, healthcare and media industries at companies that include Bristol-Myers Squibb, Elan, UnitedHealth Group Genentech, Bayer Corporation, and Kaiser Permanente.
A graduate in Communications Management at the University of Louisiana, Ms. Stutts holds a Master of Health Administration degree from the University of Southern California and completed the Executive Program in Organization and Strategy at Stanford University’s Graduate School of Business.
Renee Tannenbaum has served as a member of our board since February 2015. She currently serves as Vice President of Global Alliances at Halozyme, Inc., where she is responsible for leading the team that executes the company’s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from 2012 to 2016, where she was responsible for building commercial capabilities for the organization. Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm from 2011 to 2012 and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from 2009 to 2011, where she was responsible for revenue generation for Elan’s marketed products, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, she spent nine years at Bristol Myers Squibb and 16 years at Merck and Company where she held a variety of leadership positions in operations and general management. She retains a faculty position at the University of the Sciences’ Mayes College of Healthcare Business and Policy and serves as the Dean’s Professor. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut.
Denelle J. Waynick
A member of the Zogenix board of directors since September 2020, Ms. Waynick has more than 25 years of experience as a legal and strategic advisor across multiple sectors, including the biopharmaceutical industry. She currently serves as General Counsel and Corporate Secretary of MyoKardia. Previously, she served as Vice President, Legal Affairs (U.S.), U.S. General Counsel & Head of Global Enterprise Risk Management at UCB. During her tenure at UCB, Ms. Waynick relocated to UCB’s headquarters in Belgium for a year, where she provided counsel to the global business units, including commercial operations, R&D, and the regulatory team. Prior to UCB, Ms. Waynick oversaw legal operations as Vice President, Legal Affairs, Global Brands at Actavis, Inc. (now AbbVie) and as Legal Director at Schering-Plough (now Merck). In addition to her roles as in-house counsel, Ms. Waynick was Chief of Staff for the Office of the New Jersey Attorney General.
Ms. Waynick serves on the Board of the Atlanta Volunteer Lawyers Foundation. She holds a Juris Doctor degree from Howard University School of Law and a Bachelor of Science in Accounting from Rutgers, The State University of New Jersey, Newark.
A member of our board of directors since May 2011, Mr. Wiggins has expertise in business development activities and the marketing of pharmaceutical products, as well as management experience within the biopharmaceutical industry. Mr. Wiggins is currently the Chief Business Officer at Tracon Pharmaceuticals, a mid-stage oncology biotech company. Until 2015 Mr. Wiggins was Senior Vice President of Business Development with Elcelyx Therapeutics, Inc. Previously, he served as Chief Business Officer with Mpex Pharmaceuticals until its acquisition by Axcan in 2011. From May 1998 to February 2009, Mr. Wiggins was employed at Biogen Idec, Inc., and its predecessor Idec Pharmaceuticals, Corp., biotechnology companies, where he most recently served as Executive Vice President of Corporate and Business Development. At Idec Pharmaceuticals, Mr. Wiggins led Marketing and Business Development and was a member of the management committee for the corporate collaboration with Genentech on Rituxan®. Prior to Biogen Idec, Mr. Wiggins spent fifteen years in a number of positions of increasing responsibility in marketing, marketing research and business development at Hybridon, Inc., Schering-Plough Corporation (now Merck), Johnson & Johnson and Pfizer, Inc. Mr. Wiggins’ business development transaction experience includes closing over twenty licensing deals and several global corporate partnerships and company acquisitions. Mr. Wiggins earned his B.S. degree in Finance from Syracuse University and an M.B.A. from the University of Arizona.